ImmunityBio Has Executed Financing Transactions Resulting In Approximately $200M From Nant Capital, An Entity Affiliated With Patrick Soon-Shiong, The Company's Founder, Executive Chairman, And Global Chief Scientific And Medical Officer
Portfolio Pulse from Benzinga Newsdesk
ImmunityBio has secured approximately $200M in financing transactions from Nant Capital, an entity affiliated with Patrick Soon-Shiong, the company's founder, executive chairman, and global chief scientific and medical officer.
September 11, 2023 | 10:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ImmunityBio (IBRX) has secured significant financing from Nant Capital, which could provide the company with additional resources for its operations and potential growth.
The financing transactions provide ImmunityBio with significant capital, which could be used to fund its operations, research and development, and potential expansion. This could potentially lead to positive growth for the company, which could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100